Board of Directors & Observers
John Berton, Co-founder and Chairman of CellAegis Devices Inc.
Mr. Berton is also the co-founder and Managing Partner of Georgian Partners which he co-founded in 2008. Georgian is a growth equity stage software fund investing in Big Data Applied Analytic companies across North America. At the fund Mr. Berton is on the investment committee and focused on all aspects related to legal/financial activities in due diligence and post investment acceleration of portfolio companies. Mr. Berton also leads fund raising and oversees fund operations.
Prior to Georgian Mr. Berton was a managing director at VRG Capital, a private merchant bank where he was involved in all aspects related sourcing, financing and accelerating investments.
Mr. Berton graduated from Queen’s with a Bachelor of Arts, is a Chartered Financial Analyst.
Donna Parr, Secretary to the Board
Ms. Parr has over 25 years experience in venture capital, private equity and corporate finance working for Canadian Medical Discoveries Fund, CPP, CCFL, Continental Illinois Bank, and including twelve years in private equity at OMERS where she headed the direct equity group from 1998-2002.
Ms. Parr is currently President of Crimson Capital, a registered Exempt Market Dealer which works with companies on business development, strategy, licensing, and funding.
Ms. Parr has served on 23 boards of private, primarily venture-stage companies on behalf of institutional investors. Ms. Parr holds an MBA from York University and Masters and Honours degrees from the University of Toronto in International Relations. Ms. Parr was a Board Director of the Heart and Stroke Foundation of Ontario from 2006-2012 and is on the Commercialization Committee at the Centre for Commercialization of Regenerative Medicines.
Henry Kay, Director
Mr. Kay retired from Boston Scientific in 2006, where he was Group Vice President of New Market Development / Strategic Planning, Endosurgery Boston Scientific Corporation (BSC). Prior to joining BSC, Henry was based in the UK for five years as Senior Vice President, Sales and Marketing for Allergan Europe, a global eye care company.
Mr. Kay has 35 years of experience in the medical industry in roles which include R&D, International Marketing, Regulatory Affairs, and Strategic Planning for major pharmaceutical companies, including Schering-Plough, American Home Products, Sterling Drug and Allergan.
Mr. Kay is the U.S. Partner of Medica Venture Partners, a healthcare dedicated VC based in Israel and is an active member of two Angel Investing Groups (Boston Harbor Angels and Launchpad).
Mr. Kay is a fellow of the Royal Society of Medicine (UK). He serves on the Boards of several start up health care companies, including Smart Cells (sold to Merck in 2010), Cool Systems, Avaxia, Christcot Medical, and Cannuflow. He was a member of the board of Directors of Microfluidics, a public company in the equipment space for pharmaceutical manufacture (sold to IDEX in 2010). Internationally, he serves on the boards of 3 Canadian Medical Device companies (Cellaegis Devices and Imagistx in Toronto and Dartmouth Medical Research in Halifax). He has been a mentor with the Venture Mentoring Service of MIT. He serves on the Board of Overseers of Beth Israel-Deaconess and Newton Wellesley Hospitals.
Mr. Kay holds Bachelors (Augusta College) and Master’s Degrees in Chemistry from Rutgers University, and an MBA in International Marketing from Seton Hall University. Henry is a past President of Temple Beth Elohim in Wellesley, Massachusetts. Henry and his wife Laurie have one grown daughter and reside in Weston, Massachusetts.
Brian Roberts, Director
Mr. Roberts is a successful entrepreneur investor with broad experience in leading businesses through commercialization. Mr. Roberts has extensive experience in supply chain management with specific domain expertise in Asia Pacific.
Christopher H. Colecchi, Observer
Managing Director of Broadview Ventures, the philanthropic venture investing arm of the Paris-based Leducq Family Trust. Broadview’s mission is to accelerate the development of cures for cardiovascular diseases through investments in promising early stage companies.
Mr. Colecchi’s responsibilities include leading a team that sources and assesses potential investments, develops the investment terms, and provides guidance to portfolio companies. Mr. Colecchi also coordinates the activities of Broadview’s Strategic Advisory Board, consisting of eminent cardiologists, scientists and world-class business and investment leaders.
Previously, Mr. Colecchi was the Vice President for Research Ventures and Licensing at Partners Healthcare – an integrated health system founded in 1994 by the Harvard-affiliated Brigham and Women’s Hospital and Massachusetts General Hospital. Mr.Colecchi led business development, technology transfer, and commercialization activities at Partners and managed efforts to establish strategic alliances with the life sciences industries. He also created the Partners Innovation Fund–an internal venture capital fund that makes investments in early stage science from Partners hospitals to create start-up companies to improve patient care.
Christopher de Souza, PhD, Observer
Mr. de Souza shares responsibility for the day-to-day operations of Broadview Ventures, including business development strategy, identification and screening of new investment opportunities, negotiation of partnering terms and deal structure, as well as portfolio company board involvement. He leverages 20 years of experience in biopharmaceutical R&D, business development and corporate strategy to help meet the Broadview Ventures mission.
Mr. de Souza started his pharmaceutical career at Novartis where he was a senior scientist in the Metabolic and Cardiovascular Diseases group and then Director of Strategic Alliances with responsibilities for the therapeutic area strategy, business development and alliance management. After Novartis, Mr. de Souza was VP of Business Development at SkyePharma US Inc, a drug delivery company, where he was responsible for out-licensing SkyePharma’s clinical assets and drug delivery technologies. Christopher also founded a business development consulting practice with several clients including JSB-Partners, Diagnostics For All and Metaome.